Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 3, 2016, Pages 319-326

  Tanaka, Yoshiya ^a   Senoo, Asako ^b   Fujii, Hideji ^b   Baker, Daniel ^c  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Janssen Pharmaceutical KK   (Japan)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Biological DMARD; golimumab; remission; rheumatoid arthritis; TNF

Indexed keywords

BIOLOGICAL MARKER; FC RECEPTOR; GOLIMUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

BINDING AFFINITY; BREAST CANCER; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; HUMAN; IN VITRO STUDY; INFECTION; INJECTION SITE DISCOMFORT; MULTICENTER STUDY (TOPIC); PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; MOUSE; PROCEDURES; REMISSION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; METHOTREXATE; MICE; MICE, TRANSGENIC; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959144984     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1146682     Document Type: Review

References (44)

1. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the rheumatic diseases. Ann Rheum Dis. 2015; 74: 1037-1044.
2. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-Associated cell targets. Rheumatology (Oxford, England). 2014; 53: 1560-1569.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365: 2205-2219.
4. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569-2581.
5. Singh JA, Saag KG, Bridges SL Jr., et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum. 2016; 68: 1-26.
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344: 907-916.
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: 492-509.
8. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75: 3-15.
9. Fishwild DM, ODonnell SL, Bengoechea T, et al. High-Avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. 1996; 14: 845-851.
10. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005; 23: 1117-1125.
11. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010; 2: 428-439.
12. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-Alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007; 47: 383-396.
13. Fujii H, Murakami Y, Harada Y. Pharmacological and clinical profile of golimumab (Simponi®). Nihon Yakurigaku Zasshi. 2013; 141: 275-285.
14. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002; 25: 97-113.
15. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93: 2645-2668.
16. Shields RL, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma. R.J Biol Chem. 2001; 276: 6591-6604.
17. Gessner JE, Heiken H, Tamm A, et al. The IgG Fc receptor family. Ann Hematol. 1998; 76: 231-248.
18. Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clinical Therapeutics. 2012; 34: 77-90.
19. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81-88.
20. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-Tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2272-2283.
21. Emery P, Fleischmann R, Van Der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011; 63: 1200-1210.
22. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68: 789-796.
23. Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013; 40: 1097-1103.
24. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374: 210-221.
25. Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015; 17: 14.
26. Takeuchi T, Harigai M, Tanaka Y, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 2013; 72: 1488-1495.
27. Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012; 71: 817-824.
28. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013; 72: 381-389.
29. Weinblatt ME, Westhovens R, Mendelsohn AM, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014; 73: 2152-2159.
30. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 727-735.
31. Van Der Heijde DM, Van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989; 1: 1036-1038.
32. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005; 34: 819-836.
33. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008; 67: 189-194.
34. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-Targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011; 41: 256-264.
35. Nakashita T, Ando K, Kaneko N, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014; 4. doi: 10.1136/bmjopen-2014-005615.
36. Five-year SIMPONI data reported in treatment of signs and symptoms of moderately to severely active rheumatoid arthritis: Presented at 2013 EULAR Annual Congress. Available at
37. Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-Tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014; 73: 161-169.
38. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010; 10: 308-315.
39. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-Tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13: 1323-1332.
40. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-Alpha: structure, functn and interaction with anti-TNF agents. Rheumatology. 2010; 49: 1215-1228.
41. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009; 131: 308-316.
42. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-Tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58: 1248-1257.
43. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010; 161: 1-9.
44. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011; 63: 373-382.